retatrutide status fda Promises Big Weight Loss, but Safety Remains a Question What Is Retatrutide for Weight

Once they appear, they tend to stay unless removed with treatments like laser, chemical peels, or pigment-targeting creams

[5] proved that GIP, originally named gastric inhibitory polypeptide, could explain this incretin effect by inducing glucose-stimulated insulin secretion, and renamed the peptide as glucose-dependent insulinotropic polypeptide. Following the identification of GIP, the search for insulinotropic incretins persevered

A landmark 2023 study published in JAMA found that GLP-1 agonist users experienced increased risks of gastrointestinal adverse events (with gastroparesis risk elevated compared to patients using other diabetes medications), while a 2024 case report in PMC documented the strong relationship between semaglutide use and gastroparesis symptoms that resolved only after drug discontinuation

Thirty-nine subjects completed the study (placebo, n = 19